Stocks Health care CRMD
NASDAQ · Health careCorMedix Inc. (CRMD)
CorMedix Inc. brought in $462.2M of revenue over the twelve months to June 30, 2026. Net income was $187.2M, a net margin of 40.5%. Operating cash flow minus capital spending left $172.8M of free cash flow in fiscal 2025. At June 30, 2026 it held $256.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about CorMedix Inc.
- Net worth
- CorMedix Inc. has a market value (market cap) of $426.4M at the latest share price, and shareholders' equity of $460.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $311.7M (+617.0% year on year), with net income of $163.1M. Over the 12 months to June 30, 2026: revenue $462.2M, net income $187.2M.
- Cash flow
- In fiscal 2025 operations brought in $175M of cash; after $2.3M of capital spending, free cash flow was $172.8M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- CorMedix Inc.'s next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What CorMedix Inc. does
CorMedix Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CRMD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $311.7M | $163.1M | $2.04 | $172.8M |
| 2024 | $43.5M | -$17.9M | -$0.30 | -$50.7M |
| 2023 | n/a | -$46.3M | -$0.91 | -$38.7M |
| 2022 | $65.4K | -$29.7M | -$0.74 | -$24.6M |
| 2021 | $190.9K | -$28.2M | -$0.75 | -$22.6M |
| 2020 | $239.2K | -$22M | -$0.77 | -$22.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CRMD ranks in Health care
Latest SEC filings
What CorMedix Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Additional proxy material DEFA14A
- November 9, 2026
- November 2, 2026
- October 19, 2026
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 157% to $101.9M versus the same quarter last year; diluted EPS $0.29 versus $0.28.
- August 13, 2026
- August 7, 2026Other event 8-K
- July 2, 2026Other event 8-K
- July 1, 2026Auditor change 8-K
- June 25, 2026Form S-8 POS filing S-8 POS
What is CRMD worth? A DCF from its reported cash flow
Insider trades
What the people running CorMedix Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 4 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 18, 2026 | Dillione JanetDirector | Exercised options | 48,909 | - |
| August 29, 2026 | Zelnick Kaufman BethChief Legal Officer | Shares withheld for tax | 8,424 | $69.9K |
| August 29, 2026 | Hurlburt ElizabethChief Operating Officer | Shares withheld for tax | 8,076 | $67K |
| August 29, 2026 | Blum SusanChief Financial Officer | Shares withheld for tax | 8,424 | $69.9K |
| February 4, 2026 | Todisco JosephChief Executive Officer, Director | Received as pay | 77,156 | - |
| February 4, 2026 | Hurlburt ElizabethChief Operating Officer | Received as pay | 36,006 | - |
| February 4, 2026 | Zelnick Kaufman BethChief Legal Officer | Received as pay | 36,006 | - |
| January 26, 2026 | Duncan Gregory ScottDirector | Received as pay | 30,453 | - |
Who owns CRMD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| CorMedix Inc.13D, may seek influence | 19.95% | September 12, 2025 |
| Deep Track Capital, LP13G, passive with 2 related filers | 7.94% | May 15, 2026 |
| Shaibatalhamd Aymen Abdalkader13G, passive | 5.9% | June 12, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 194 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 6,324,111 | +356,536 |
| Deep Track Capital, LP | 6,274,076 | 0 |
| Vanguard Capital Management LLC | 3,135,075 | +5,419 |
| State Street Corp | 2,316,845 | +125,002 |
| Royce & Associates LP | 2,176,362 | +288,830 |
| Geode Capital Management, LLC | 1,947,014 | +130,107 |
| UBS Group AG | 1,877,940 | +339,695 |
| Oberweis Asset Management Inc/ | 1,323,915 | +112,800 |
| Alyeska Investment Group, L.P. | 850,000 | 0 |
| Marshall Wace, Llp | 779,535 | +276,570 |
| Northern Trust Corp | 756,430 | +118,747 |
| Vanguard Portfolio Management LLC | 708,604 | -33,967 |
| Trexquant Investment LP | 623,797 | +63,160 |
| Charles Schwab Investment Management Inc | 618,172 | +15,206 |
| Armistice Capital, LLC | 500,000 | new |
| Vanguard Fiduciary Trust Co | 484,322 | -21,357 |
| Goldman Sachs Group Inc | 466,393 | -44,936 |
| Raymond James Financial Inc | 446,142 | +117,918 |
| Hennion & Walsh Asset Management, Inc. | 438,629 | +263,618 |
| Bridgeway Capital Management, LLC | 434,132 | new |
Insiders
11 insiders reported holding 2,244,582 shares in total, about $12.3M at the last price.
| Holder | Shares |
|---|---|
| Todisco JosephChief Executive Officer, Director | 774,749 |
| Hurlburt ElizabethChief Operating Officer | 270,463 |
| Zelnick Kaufman BethChief Legal Officer | 260,684 |
| Kaplan MyronDirector | 231,487 |
| Seckler Michael DavidChief Commercial Officer | 133,156 |
| Lefkowitz Steven WDirector | 125,951 |
| Blum SusanChief Financial Officer | 124,315 |
| Dillione JanetDirector | 117,835 |
| Dunton Alan WDirector | 70,703 |
| Duncan Gregory ScottDirector | 68,786 |
Questions about CRMD
What does CorMedix Inc. do?
CorMedix Inc. is a company in the Health care sector, listed on NASDAQ as CRMD. Its shares trade on NASDAQ under the ticker CRMD.
What is CorMedix Inc.'s net worth?
CorMedix Inc. has a market value (market cap) of $426.4M at the latest share price, and shareholders' equity of $460.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is CorMedix Inc. profitable?
Yes. Over the twelve months to June 30, 2026 it reported net income of $187.2M on revenue of $462.2M, a net margin of 40.5%.
How much revenue does CorMedix Inc. make?
Over the twelve months to June 30, 2026 CorMedix Inc. reported revenue of $462.2M.
When did CorMedix Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the additional proxy material from November 9, 2026.
When is CorMedix Inc.'s next earnings report?
CorMedix Inc.'s next report is expected around January 7, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CRMD with
Follow CRMD
Get an email when CorMedix Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values CorMedix Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.